Connect with us

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Teva Pharmaceuticals Industries Limited of Class Action Lawsuit and Upcoming Deadline – TEVA

NEW YORK, Oct. 17, 2020 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Teva Pharmaceuticals Industries Limited (“Teva” or the “Company”) (NYSE: TEVA) and certain of its officers. The class action, filed in United States District Court for the…




NEW YORK, Oct. 17, 2020 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Teva Pharmaceuticals Industries Limited (“Teva” or the “Company”) (NYSE: TEVA) and certain of its officers.  The class action, filed in United States District Court for the Eastern District of Pennsylvania, and docketed under 20-cv-04660, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquired Teva securities between October 29, 2015 and August 18, 2020, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased Teva securities during the class period, you have until November 23, 2020, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at   To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here for information about joining the class action] 

Teva, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally.

Among Teva’s products is Copaxone (glatiramer acetate), a prescription drug that is used to treat relapsing forms of multiple sclerosis (“MS”).  Throughout the Class Period, Teva consistently described Copaxone as the Company’s “leading specialty medicine,” reporting Copaxone sales and revenues that consistently dwarfed the same metrics for other Teva specialty products.  Teva attributed Copaxone’s commercial success to “having the right mix” of, among other things, “a fantastic underlying demand,” “patients hav[ing] access to it,” and an “unparalleled . . . track record of both efficacy and safety.”

The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational, and compliance policies.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Teva had made substantial illegal kickback payments to charitable foundations to cover Medicare co-payment obligations of patients taking Copaxone; (ii) accordingly, Teva’s revenues derived from Copaxone were in part the product of unlawful conduct and thus unsustainable; (iii) the foregoing misconduct subjected Teva to a foreseeable risk of heightened regulatory scrutiny and enforcement, as well as reputational harm when the truth became known; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On August 18, 2020, the United States Department of Justice (“DOJ”) issued a press release announcing that it had filed a complaint against Teva under the False Claims Act.  Specifically, “[t]he government alleges that, from 2007 through 2015, Teva paid The Assistance Fund (TAF) and Chronic Disease Fund (CDF) with the intent and understanding that the foundations would use Teva’s money to cover the Medicare co-pays of patients taking Copaxone.  During the same period, Teva raised the price of Copaxone from approximately $17,000 per year to over $73,000 per year.” 

On this news, Teva’s American depositary receipt (“ADR”) price fell $1.11 per ADR from its previous close on August 17, 2020, or 9.6%, to close at $10.48 per ADR on August 18, 2020, on unusually heavy trading volume.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See

Robert S. Willoughby
Pomerantz LLP
[email protected] 
888-476-6529 ext. 7980

SOURCE Pomerantz LLP

Related Links


Continue Reading

Press Releases

Jim Erpenbach DDS offers advanced aesthetic dental therapy using biomimetic dentistry techniques.

Dr. Erpenbach is a well-known dentist in Knoxville, TN. He and his team utilize biomimetic dentistry to create dental work that imitates the natural teeth as closely as possible. With carefully selected materials and the most up-to-date sciences, technology, and techniques, they can produce second-to-none dental work. The team at Dr. Erpenbach strives to provide… Read more »

The post Jim Erpenbach DDS offers advanced aesthetic dental therapy using biomimetic dentistry techniques. first appeared on PRUnderground.




Industry: Medical

Jim Erpenbach DDS is a Knoxville based dental clinic specializing in aesthetic dental therapy.

Knoxville, TN (PRUnderground) October 30th, 2020

Dr. Erpenbach is a well-known dentist in Knoxville, TN. He and his team utilize biomimetic dentistry to create dental work that imitates the natural teeth as closely as possible. With carefully selected materials and the most up-to-date sciences, technology, and techniques, they can produce second-to-none dental work.

The team at Dr. Erpenbach strives to provide its clients with the best dental care. Knoxville, TN residents, are well aware when they visit Dr. Erpenbach, they receive treatment with the most up-to-date and latest dental advancements.

Dr. Erpenbach earned his undergraduate degree in 1982 from the University of Tennessee, Memphis. He has been practicing dentistry for over twenty-eight years. The team also averages one hundred and fifty hours of continuing education every year, and Dr. Erpenbach trains other dentists in biomimetic dentistry. 

Dr. Erpenbach is also a founding member of the American Academy of Oral Systemic Health and a member of the Crown Council and American Dental Association. 

At Jim Erpenbach DDS, patients can receive unparalleled care with biomimetic dentistry, which is preventative dentistry, differing from traditional dentistry. The goal is to preserve as much of the natural tooth structure as possible. 

Rather than drilling down the teeth, the team works to rebuild and protect them during the restoration process using ozone treatments, cleaning, and sealants. The clinic’s qualified cosmetic dentists team also performs a wide range of cosmetic dentistry services such as porcelain veneers, prepless veneers, teeth whitening, etc. 

Aside from biomimetic and cosmetic dentistry, Dr. Erpenbach and his team are proud to offer a wide range of additional services, including family dentistry, gum disease treatment, emergency dental care, laser dentistry, systematic oral dentistry, and TMD/TMJ treatment. 

Those interested in learning more about the services offered at Jim Erpenbach DDS are invited to fill out a patient form on the website

About Jim Erpenbach DDS

Print Friendly, PDF & Email


Continue Reading

Press Releases

Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira® in Moderate-to-Severe Psoriasis Patients

BRUSSELS, Oct. 31, 2020 /PRNewswire/ — UCB, a global biopharmaceutical company, today announced the detailed results of the head-to-head Phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved superior skin…




BRUSSELS, Oct. 31, 2020 /PRNewswire/ — UCB, a global biopharmaceutical company, today announced the detailed results of the head-to-head Phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved superior skin clearance, as compared to adalimumab, in adults with moderate-to-severe plaque psoriasis.1 These findings were presented for the first time as an oral presentation at the European Academy of Dermatology and Venereology Congress, taking place virtually between October 29-31, 2020.

BE SURE met all primary and secondary ranked endpoints.1 The co-primary endpoints were at least a 90 percent improvement in the Psoriasis Area and Severity Index (PASI 90) and Investigator Global Assessment (IGA) of clear or almost clear (IGA 0/1) versus adalimumab at week 16. Secondary endpoints included PASI 90 and IGA 0/1 at weeks 24 and 56, and PASI 100 at weeks 16 and 24.

In BE SURE, patients treated with bimekizumab achieved significantly higher PASI 90, IGA 0/1 and PASI 100 skin clearance rates compared to patients treated with adalimumab at week 16.1 In patients that started bimekizumab at baseline, response rates were maintained up to a year. Rapid increases in skin clearance rates were seen in patients who switched from adalimumab to bimekizumab at week 24.1 The safety and efficacy of bimekizumab have not been established, and it is not approved by any regulatory authority worldwide.

“In BE SURE, we saw significantly higher skin clearance rates with bimekizumab compared with one of the most commonly used biologic treatments in psoriasis. The study results also demonstrated the potential benefits of switching patients who are being treated with adalimumab to bimekizumab,” said study investigator, Professor Richard Warren, Salford Royal NHS Foundation Trust and The University of Manchester, United Kingdom.

“These findings from BE SURE, the third positive study in the psoriasis clinical development program, are further evidence of bimekizumab’s superior depth of response. The results also add to the mounting evidence supporting the potential value of selective inhibition of IL-17F, in addition to IL-17A, for rapid, complete and durable skin clearance, if approved by health authorities. UCB is proud to be developing innovative solutions for psoriasis patients,” said Emmanuel Caeymaex, Executive Vice President Immunology Solutions and Head of US, UCB.

In BE SURE, 86.2 percent of patients treated with bimekizumab achieved almost clear skin (PASI 90), compared with 47.2 percent of patients treated with adalimumab at week 16 (p<0.001).1 Additionally, 85.3 percent of patients treated with bimekizumab achieved IGA 0/1, versus 57.2 percent of patients treated with adalimumab at week 16 (p<0.001).1 Significantly more patients treated with bimekizumab achieved complete skin clearance (PASI 100) than those treated with adalimumab: 60.8 percent versus 23.9 percent at week 16, and 66.8 percent versus 29.6 percent at week 24 (p<0.001 for each comparison).1 

In the two bimekizumab study arms, PASI 90, PASI 100 and IGA 0/1 response rates were maintained through to week 56.1 These results were observed across both dosing regimens: bimekizumab every four weeks (Q4W dosing) until week 56, or Q4W dosing for 16 weeks, followed by bimekizumab every eight weeks (Q8W dosing) from week 16 to week 56.1 In patients treated with adalimumab, response rates for PASI 90, PASI 100 and IGA 0/1 rapidly increased after patients were switched to bimekizumab Q4W dosing at week 24, through to week 56.1 At week 56, response rates in switched patients were comparable to those who had been treated with bimekizumab throughout the study.1 

Through weeks 0–24, the active comparator period, treatment emergent adverse events (TEAEs) and serious TEAEs were comparable for patients receiving bimekizumab (71.5 percent and 1.6 percent, respectively) and adalimumab (69.8 percent and 3.1 percent).1 Through weeks 0–56, 81.4 percent and 5.1 percent of patients receiving bimekizumab (including those who switched from adalimumab) experienced TEAEs and serious TEAEs, respectively.1 The most common TEAEs that were observed for bimekizumab through weeks 0–56 were nasopharyngitis (20.9 percent), oral candidiasis (16.2 percent) and upper respiratory tract infection (9.0 percent).1 Through week 56, there were no suicidal ideation/behavior, inflammatory bowel disease, or major adverse cardiac events reported in patients treated with bimekizumab.1 

About BE SURE                                                                                                                
BE SURE is a Phase 3, randomized, double-blind study comparing the efficacy and safety of bimekizumab to adalimumab in adult patients with moderate-to-severe chronic plaque psoriasis. The active-controlled initial treatment period of 24 weeks is followed by a dose-blind maintenance treatment period until week 56. BE SURE enrolled 478 participants with chronic plaque psoriasis for at least six months prior to screening and with an affected body surface area of at least 10 percent, PASI of at least 12 and IGA score equal to or greater than three on a five-point scale.2

The co-primary endpoints of the study were PASI 90 response (defined as a patient who achieves a 90 percent improvement in PASI) and IGA response (defined as clear or almost clear with at least a two-category improvement relative to baseline) at week 16. For additional details on the study, visit BE SURE on UCB announced topline findings from BE SURE in December 2019. For additional details, visit: BE SURE on

Humira® is a registered trademark of AbbVie, Inc.

About Bimekizumab
Bimekizumab is an investigational humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F, two key cytokines driving inflammatory processes.3 IL-17F has overlapping biology with IL-17A and drives inflammation independently to IL-17A.4,5,6,7,8 Selective inhibition of IL-17F in addition to IL-17A suppresses inflammation to a greater extent than IL-17A inhibition alone.7,8 The safety and efficacy of bimekizumab are being evaluated across multiple disease states as part of a robust clinical program.

About Psoriasis
Psoriasis is a common, chronic inflammatory disease with primary involvement of the skin. This skin condition affects men and women of all ages and ethnicities.9 Psoriasis signs and symptoms can vary but may include red patches of skin covered with silvery scales; dry, cracked skin that may bleed; and thickened, pitted or ridged nails.10

Psoriasis affects nearly three percent of the population, or about 125 million people worldwide.6 Unmet needs remain in the treatment of psoriasis. A population-based survey identified that approximately 30 percent of psoriasis patients reported that their primary goals of therapy, including keeping symptoms under control, reducing itching and decreasing flaking, were not met with their current treatment.11 Psoriasis has a considerable psychological and quality of life impact, potentially affecting work, recreation, relationships, sexual functioning, family and social life.12

About UCB
UCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7,600 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

Forward looking statements UCB
This press release may contain forward-looking statements including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: the global spread and impact of COVID-19, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, will progress to product approval or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB’ efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB’s products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB’s data and systems.

Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future.

UCB is providing this information, including forward-looking statements, only as of the date of this press release and it does not reflect any potential impact from the evolving COVID-19 pandemic, unless indicated otherwise. UCB is following the worldwide developments diligently to assess the financial significance of this pandemic to UCB. UCB expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

For further information, UCB:

Corporate Communications

Laurent Schots,

Media Relations, UCB

Investor Relations

Antje Witte,                   
Investor Relations, UCB

Brand Communications

Andrea Christopher,

Immunology Communications, UCB

[email protected]

T +32.2.559.94.14,
[email protected]

T +1.404.483.7329

[email protected]

Investor Relations

Isabelle Ghellynck,

Investor Relations, UCB

[email protected]


Warren R, Blauvelt A, Bagel J, et al. Bimekizumab efficacy and safety versus adalimumab in patients with moderate to severe plaque psoriasis: Results from a multicentre, randomised, double-blinded active comparator-controlled phase 3 trial (BE SURE). Abstract ID 1958. Presented at the virtual 29th European Academy of Dermatology and Venereology Congress, October 29-31, 2020.

2 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE SURE). Available at: Last accessed: October 2020.


Glatt S, Helmer E, Haier B, et al. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis. Br J Clin Pharmacol. 2017;83(5):991-1001.


Yang XO, Chang SH, Park H, et al. Regulation of inflammatory responses by IL-17F. J Exp Med. 2008;205(5):1063–1075.


Hymowitz SG, Filvaroff EH, Yin JP, et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. Embo J. 2001;20(19):5332–5341.


van Baarsen LG, Lebre MC, van der Coelen D, et al. Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy? Arthritis Res Ther. 2014;16(4):426.


Maroof A, Okoye R, Smallie T, et al. Bimekizumab dual inhibition of IL-17A and IL-17F provides evidence of IL-17F contribution to chronic inflammation in disease-relevant cells. Ann Rheum Dis. 2017;76(2):213.


Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523-532.


National Psoriasis Foundation. Statistics. Available at: Last accessed: October 2020.


International Federation of Psoriasis Associations. Available at: Last accessed: October 2020.


Lebwohl MG, Kavanaugh A, Armstrong AW et al. US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Am J Clin Dermatol. 2016; 17(1):87-97.


Moon HS, Mizara A, McBride SR. Psoriasis and psycho-dermatology. Dermatol Ther (Heidelb). 2013;3:117-130.




Continue Reading

Press Releases

Garbage Guy offering junk removal services in the Phoenix, Az area.

Garbage Guy is a locally owned and operated company that serves the greater Phoenix valley, Arizona. The team at Garbage Guy has proudly helped Arizona communities get rid of their junk since 2015 and have made over 17,000 stops.  Whether it is a job left by a construction team, a home office renovation, or a… Read more »

The post Garbage Guy offering junk removal services in the Phoenix, Az area. first appeared on PRUnderground.




Industry: Home & Residential

Garbage Guy is a junk removal company that offers a variety of junk removal services in the greater Arizona area.

Phoenix, AZ (PRUnderground) October 30th, 2020

Garbage Guy is a locally owned and operated company that serves the greater Phoenix valley, Arizona. The team at Garbage Guy has proudly helped Arizona communities get rid of their junk since 2015 and have made over 17,000 stops. 

Whether it is a job left by a construction team, a home office renovation, or a remodeling job, the Garbage Guy team can be there to collect and dispose of the junk efficiently. From an early age, Robert Allen also known as Garbage Guy was keen on cleanliness. It started from an early age when he would always take out the trash at home, initially by request, then becoming a habit.

Garbage Guy’s team of specialists are trained and equipped with all the necessary tools, equipment, and cleaning supplies needed to leave any space looking brand new after removing all the trash. Garbage Guy proudly differentiates themselves from the competition with a truck two feet longer; no mess is too large for the Garbage Guy team. 

The services provided include junk removal, moving box and packing material, old furniture, appliances, yard debris, remodeling debris, estate cleanouts, clean rental outs, event clean up, real estate curb appeal, and dumpster cleanups, construction site cleanups, and more. 

Robert Allen and his team at Garbage Guy are proud to offer the best junk removal in Phoenix, Az. All Junk removal is done so sustainably; Garbage Guy is committed to making Arizona cleaner by doing their part. In order to reduce waste as much as possible, all garbage is sorted through. 

While some are recycled and donated, others are correctly disposed of in landfills. All recyclable materials are donated to local charities to be put to better use, such as Goodwill, Salvation Army, A New Leave, and House of Refuge. 

Garbage Guy and his team are well-known for being the most reliable junk removal company in Phoenix, Az by making it easy to dispose of any junk, old appliances, and more. To learn more about the services and locations offered, visit the official website. 

About Garbage Guy Inc

Print Friendly, PDF & Email


Continue Reading